Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

University College, London: Clinical Trials & FDA Approval Profile

University College, London (Global / Institutional) sponsors 77 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 36 active protocols (21 recruiting now), 20 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)7.8%
Median Closed Enrollment vs National (145 pts)49 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for University College, London
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)77
Active Pipeline (Recruiting Now)36 (21)
Completed vs Stopped Early20 / 6 (7.8%)
Median Closed Actual Enrollment49 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With University College, London
Hospital Research SiteLocationShared Protocols
University College London HospitalLondon14
Churchill HospitalOxford12
Beatson West of Scotland Cancer CentreGlasgow8

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by University College, London
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT03288532Renal Adjuvant MultiPle Arm Randomised TrialPhase IIIRECRUITING
NCT06762769Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering MyelomaPhase IIRECRUITING
NCT06320067A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate CancerPhase IIIRECRUITING
NCT04061512Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaePhase II/IIIRECRUITING
NCT05185739Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)Phase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the University College, London Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI